Table of Contents
Chapter 1. Global GLP-1 Analogues Market Executive Summary
1.1. Global GLP-1 Analogues Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Format
1.3.3. By Route of Administration
1.3.4. By Indication
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global GLP-1 Analogues Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global GLP-1 Analogues Market Dynamics
3.1. Market Drivers
3.1.1. Strong R&D Pipeline
3.1.2. Increasing Prevalence of Chronic Diseases
3.2. Market Challenges
3.2.1. High Entry Barriers Due to Duopoly
3.2.2. Non-adherence to Therapy
3.3. Market Opportunities
3.3.1. Extended Therapeutic Uses
3.3.2. Development of Oral GLP-1 Analogues
Chapter 4. Global GLP-1 Analogues Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global GLP-1 Analogues Market Size & Forecasts by Product 2022-2032
5.1. Segment Dashboard
5.2. Global GLP-1 Analogues Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Ozempic
5.2.2. Wegovy
5.2.3. Rybelsus
5.2.4. Saxenda
5.2.5. Victoza
5.2.6. Trulicity
5.2.7. Mounjaro
5.2.8. Zepbound
5.2.9. Soliqua
5.2.10. Xultophy
5.2.11. Bydureon
5.2.12. Other products
Chapter 6. Global GLP-1 Analogues Market Size & Forecasts by Format 2022-2032
6.1. Segment Dashboard
6.2. Global GLP-1 Analogues Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Single-dose
6.2.2. Multi-dose
6.2.3. Tablets
Chapter 7. Global GLP-1 Analogues Market Size & Forecasts by Route of Administration 2022-2032
7.1. Segment Dashboard
7.2. Global GLP-1 Analogues Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Subcutaneous
7.2.2. Oral
Chapter 8. Global GLP-1 Analogues Market Size & Forecasts by Indication 2022-2032
8.1. Segment Dashboard
8.2. Global GLP-1 Analogues Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Diabetes
8.2.2. Obesity
8.2.3. Other indications
Chapter 9. Global GLP-1 Analogues Market Size & Forecasts by End User 2022-2032
9.1. Segment Dashboard
9.2. Global GLP-1 Analogues Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospitals and Specialty Clinics
9.2.2. Long-term Care Facilities
9.2.3. Home Care Settings
Chapter 10. Global GLP-1 Analogues Market Size & Forecasts by Region 2022-2032
10.1. North America GLP-1 Analogues Market
10.1.1. U.S. GLP-1 Analogues Market
10.1.1.1. Product breakdown size & forecasts, 2022-2032
10.1.1.2. Format breakdown size & forecasts, 2022-2032
10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.4. Indication breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada GLP-1 Analogues Market
10.2. Europe GLP-1 Analogues Market
10.2.1. U.K. GLP-1 Analogues Market
10.2.2. Germany GLP-1 Analogues Market
10.2.3. France GLP-1 Analogues Market
10.2.4. Spain GLP-1 Analogues Market
10.2.5. Italy GLP-1 Analogues Market
10.2.6. Rest of Europe GLP-1 Analogues Market
10.3. Asia-Pacific GLP-1 Analogues Market
10.3.1. China GLP-1 Analogues Market
10.3.2. India GLP-1 Analogues Market
10.3.3. Japan GLP-1 Analogues Market
10.3.4. Australia GLP-1 Analogues Market
10.3.5. South Korea GLP-1 Analogues Market
10.3.6. Rest of Asia Pacific GLP-1 Analogues Market
10.4. Latin America GLP-1 Analogues Market
10.4.1. Brazil GLP-1 Analogues Market
10.4.2. Mexico GLP-1 Analogues Market
10.4.3. Rest of Latin America GLP-1 Analogues Market
10.5. Middle East & Africa GLP-1 Analogues Market
10.5.1. Saudi Arabia GLP-1 Analogues Market
10.5.2. South Africa GLP-1 Analogues Market
10.5.3. Rest of Middle East & Africa GLP-1 Analogues Market
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Novo Nordisk A/S
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Eli Lilly and Company
11.3.3. Sanofi
11.3.4. AstraZeneca
11.3.5. Boehringer Ingelheim International GmbH
11.3.6. Innovent
11.3.7. Hanmi Pharm
11.3.8. Zealand Pharma A/S
11.3.9. Pfizer, Inc.
11.3.10. GlaxoSmithKline plc
11.3.11. Johnson & Johnson
11.3.12. Merck & Co., Inc.
11.3.13. Teva Pharmaceutical Industries Ltd.
11.3.14. Bristol-Myers Squibb Company
11.3.15. Roche Holding AG
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes